FDA Expands Use of Durvalumab to Non–small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
Tag: Lung cancer
The U.S. Food and Drug Administration (FDA) recently approved expanding the use of the immunotherapeutic durvalumab (Imfinzi) to include...
A diverse group of about 220 physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research...
Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing...
Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung...
Hot on the heels of the FDA’s landmark approval of an anticancer therapeutic for use based on whether a...
Last week, a flurry of U.S. Food and Drug Administration (FDA) oncology approvals concluded with the approval of the...
This past week has included good news for some patients with lung cancer and bad news for those with...
Earlier this week, the U.S. Food and Drug Association (FDA) announced it had approved the immunotherapeutic atezolizumab (Tecentriq) for...
Cancer Today Senior Editor Marci A. Landsmann shares her experience reporting on a young lung cancer survivor, Emily Bennett...
Dr. Patricia LoRusso works to find innovative therapeutics to reduce the toll of cancer on patients and their families.